Dualitybio Inc.

2 trials Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

1 Completed trials

7 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 1 Phase II: 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hormone receptor positive HER2 negative breast cancer 1 Squamous cell carcinoma of head and neck 1 Ovarian cancer 1 Non-small cell lung cancer 1

Top IMPs

BNT324 1 BNT327 1 DB-1303 1 HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE 1

All trials

2 total

DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending

2025-523895-22-00 Phase II 5 countries BNT324; BNT327; HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N…
A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended

2023-507333-17-00 Phase III 7 countries DB-1303

Showing 1–2 of 2 trials

← All sponsors A–Z